Thiam M. auteur aut IRD Diop-Ndiaye H. auteur aut IRD Diouf A. D. auteur aut IRD Vidal Nicole auteur aut IRD Ndiaye O. auteur aut IRD Ndiaye I. auteur aut IRD Ngom-Gueye N. F. auteur aut IRD Diallo S. auteur aut IRD Diongue O. D. auteur aut IRD Camara M. auteur aut IRD Seck A. auteur aut IRD Mboup S. auteur aut IRD Toure-Kane C. auteur aut IRD text journalArticle eng text/pdf born digital access In this study, we investigated the prevalence of human immunodeficiency virus type 1 (HIV-1) drug resistance mutations and genetic variability among Senegalese patients undergoing highly active antiretroviral therapy (ART) in the public health system. We conducted a cross-sectional study of 72 patients with suspected therapeutic failure. HIV-1 genotyping was performed with Viroseq HIV-1 Genotyping System v2.0 or the procedure developed by the ANRS AC11 resistance study group, and a phylogenetic analysis was performed. The median follow-up visit was at 40 (range, 12 to 123) months, and the median viral load was 4.67 (range, 3.13 to 6.94) log(10) copies/ml. The first-line therapeutic regimen was nucleoside reverse transcriptase inhibitors (NRTIs) plus efavirenz (EFV) or NRTIs plus nevirapine (NVP) (54/72 patients; 75%), and the second-line therapy was NRTIs plus a protease inhibitor (PI/r) (18/72; 25%). Fifty-five patients (55/72; 76.39%) had at least one drug resistance mutation. The drug resistance rates were 72.22 and 88.89% for the first-line and second-line ARTs, respectively. In NRTI mutations, thymidine analog mutations (TAMs) were found in 50.79% and the M184V mutation was found in 34.92% of the samples. For non-NRTI resistance, we noted a predominance of the K103N mutation (46.27%). For PI/r, several cases of mutations were found with a predominance of M46I and L76V/F at 24% each. The phylogenetic analysis revealed CRF02_AG as the predominant circulating recombinant form (43/72; 59.72%). We found a high prevalence of resistance mutations and a high rate of TAMs among Senegalese patients in the public health system. These findings emphasize the need to improve virological monitoring in resource-limited settings. specialized SENEGAL 052 050 51 2 578-584 2013 0095-1137 https://www.documentation.ird.fr/hor/PAR00010187 10.1128/jcm.02452-12 0095-1137 [F B010087035] https://www.documentation.ird.fr/hor/PAR00010187 https://www.documentation.ird.fr/intranet/publi/2022-12/010087035.pdf Accès réservé (Intranet de l'IRD) IRD - Base Horizon / Pleins textes 2013-04-02 2022-12-19 PAR00010187 fre